Cat:GMP-h-CEA
Awaiting product image
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-h-CEA Categories ,

For more than 100mg, click here for inquiry. >>

Product Details

Genemedi produces core diagnostic ingredients for test of Cancer (breast cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, ovarian cancer) and related syndrome. GeneMedi offers paired diagnostics grade carcinoembryonic antigen (CEA) antibodies (monoclonal antibody, mab) and antigens for Cancer (breast cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, ovarian cancer) rapid test kit of carcinoembryonic antigen (CEA) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Cancer (breast cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, ovarian cancer ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Carcinoembryonic antigens are proteins produced by some types of cancer. A carcinoembryonic antigen (CEA) diagnosis is used to check efficiency of cancer treatment. A CEA test is often carried out after surgery to check carcinoembryonic antigen levels. CEA can be used to assess different types of cancer, such as breast cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, ovarian cancer

Product Description

Cat No. of Pruducts

GMP-h-CEA-Ag01:Recombinant Human CEA Protein

Product Name

Recombinant Human CEA Protein

Target

carcinoembryonic antigen

Alias of Target/Biomarker

#N/A

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

carcinoembryonic antigen (CEA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in CEA level test of Cancer (breast cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, ovarian cancer) and related syndrome evaluation

Tag

His

Products description

Recombinant Human CEA Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-h-CEA-Ab01,GMP-h-CEA-Ab02:Anti-Human CEA mouse monoclonal antibody (mAb)

Product Name

Anti-Human CEA mouse monoclonal antibody (mAb)

Target

Alias of Target/Biomarker

#N/A

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

Human Carcinoembryonic antigen (CEA) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Carcinoembryonic antigen (CEA) antibodies in CEA level test of Cancer (breast cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, ovarian cancer) and related syndrome evaluation.

Tag

mFc

Products description

Anti-Human CEA mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Carcinoembryonic antigen (CEA) antibodies.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.